A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

<table>Time-course changes in score of anorexia. Each plot refers to mean ± SD. There were no significant differences in score change between the TJ-43 treated group and the TJ-43 non-treated group (Wilcoxon’s rank sum test).</table>

International Journal of Surgical Oncology

fig5

Figure 5

Figure 5: A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP 

Figure 5 | A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP 